Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study on Camrelizumab Combined with Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)

NCT04952571 is registered in ClinicalTrials.gov with Beijing Sanbo Brain Hospital as lead sponsor.

NCT NCT04952571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04952571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study on Camrelizumab Combined with Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)
Lead sponsor
Beijing Sanbo Brain Hospital
Phase
Phase 2
Overall status
Terminated
Start date
June 27, 2021
Completion date
December 31, 2022
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma